{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'LIST OF TABLES', 'Table 1:', 'Schedule of Events: Screening and Treatment Period', '53', 'Table 2:', 'Schedule of Events, Post-Treatment Follow-Up', '56', 'Table 3:', 'Schedule of Events for Cemiplimab Extension Phase', '59', 'Table 4:', 'General Guidelines for Cemiplimab Treatment Modifications or', 'Discontinuations Due to Adverse Events', '73', 'Table 5:', 'General Treatment Hold Guidelines for Immune Related Adverse Events', '74', 'Table 6:', 'Cemiplimab Dose Reductions', '74', 'Table 7:', 'Dose Reductions for Pemetrexed: Hematologic Toxicity', '77', 'Table 8:', 'Dose Reductions for Pemetrexed: Nonhematologic Toxicity', '77', 'Table 9:', 'Dose Reductions for Topotecan', '78', 'Table 10:', 'Recommended Dose Modifications for Irinotecan Monotherapy', '79', 'Table 11:', 'Dose Modifications for Gemcitabine for Myelosuppression on Day of', 'Treatment', '80', 'Table 12:', 'Gemcitabine Dose Modifications for Myelosuppression in Preceding Cycle', '80', 'Table 13: Vinorelbine Dose Modifications for Neutropenia', '81', 'Table 14: Vinorelbine Dose Modifications for Elevated Bilirubin', '81', 'Table 15: Alpha Spending in Group Sequential Design Using Lan-DeMets', \"(O'Brien-Fleming) Spending Function\", '100', 'LIST OF FIGURES', 'Figure 1: TCGA Immune Signatures Using CD8A/PD-1/PD-L1 Expression', '37', 'Figure 2: Study Design Schematic', '45', 'LIST OF APPENDICES', 'APPENDIX 1. RESPONSE EVALUATION CRITERIA IN SOLID TUMORS:', 'RECIST GUIDELINE (VERSION 1.1)', '112', 'APPENDIX 2. RECOMMENDED DOSE MODIFICATION OR', 'DISCONTINUATION AND SUPPORTIVE CARE GUIDELINES FOR', 'SPECIFIC CEMIPLIMAB RELATED ADVERSE EVENTS', '118', 'APPENDIX 3. MEDDRA DICTIONARY-DERIVED PREFERRED TERMS FOR', 'POTENTIAL IRAES', '132', 'APPENDIX 4. FACTORS TO CONSIDER IN ASSESSING THE RELATIONSHIP', 'OF ADVERSE EVENTS TO STUDY DRUG, STUDY CONDUCT,', 'INFUSION PROCEDURE, OR STUDY PROCEDURE', '144', 'Regeneron Pharmaceuticals, Inc.', 'Page 26 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'CLINICAL STUDY PROTOCOL SYNOPSIS', 'Title', 'An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus', \"Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical\", 'Carcinoma', 'Site Location(s)', 'Patients will be enrolled at approximately 100 sites globally.', 'Principal Investigator', 'The Principal Investigator is to be determined.', 'Objectives', 'The primary objective is to compare overall survival (OS) for patients with', 'recurrent or metastatic cervical cancer who have histology of squamous cell', 'carcinoma (SCC) and who have any eligible histology, treated with either', \"REGN2810 (cemiplimab) or investigator's choice (IC) chemotherapy.\", 'The secondary objectives performed among SCC patients and among all', 'eligible histologies (SCC and adenocarcinoma/adenosquamous carcinoma', '[AC]) are:', 'To compare progression-free survival (PFS) of cemiplimab versus', 'IC chemotherapy', 'To compare objective response rate (ORR) (partial response [PR]', '+', 'complete response [CR]) of cemiplimab versus IC chemotherapy', 'per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1', 'To compare the duration of response (DOR) of cemiplimab versus', 'IC chemotherapy', 'To compare the safety profiles of cemiplimab versus IC', 'chemotherapy by describing adverse events (AE)', 'To compare quality of life (QOL) for patients treated with', 'cemiplimab versus IC chemotherapy using the European', 'Organization for Research and Treatment of Cancer Quality of Life', 'Questionnaire-Core 30 (EORTC QLQ-C30)', 'Study Design', 'This is an open-label, randomized, multi-center, phase 3 trial comparing', 'cemiplimab versus IC of chemotherapy in patients with recurrent or', 'metastatic cervical cancer. Approximately 590 patients will be randomized', 'to either the experimental cemiplimab treatment arm or the IC of', 'chemotherapy control treatment arm. In the experimental group,', 'cemiplimab will be administered intravenously (IV) as a flat dose of 350 mg', 'every 3 weeks (Q3W). In the control group, IC chemotherapy options are', '4 classes: (1) antifolate - pemetrexed, (2) topoisomerase 1', 'inhibitor - topotecan or irinotecan, (3) nucleoside analogue - gemcitabine,', 'and (4) vinca alkaloid - vinorelbine. The only chemotherapy treatments', 'allowed in the control arm are any of the 5 drugs that are listed as IC options.', 'Other agents in these classes are not permitted in this study.', 'Regeneron Pharmaceuticals, Inc.', 'Page 27 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}